company background image
ALDV

Advicenne ENXTPA:ALDVI Stock Report

Last Price

€4.60

Market Cap

€45.5m

7D

7.5%

1Y

-50.5%

Updated

20 May, 2022

Data

Company Financials +
ALDVI fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

ALDVI Stock Overview

Advicenne S.A., a specialty pharmaceutical company, develops and commercializes treatments for nephrology.

Advicenne Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Advicenne
Historical stock prices
Current Share Price€4.60
52 Week High€10.50
52 Week Low€3.73
Beta1.51
1 Month Change-16.36%
3 Month Change-32.55%
1 Year Change-50.54%
3 Year Change-54.00%
5 Year Changen/a
Change since IPO-67.14%

Recent News & Updates

Shareholder Returns

ALDVIFR PharmaceuticalsFR Market
7D7.5%2.4%-1.3%
1Y-50.5%15.9%-5.4%

Return vs Industry: ALDVI underperformed the French Pharmaceuticals industry which returned 13.8% over the past year.

Return vs Market: ALDVI underperformed the French Market which returned -4.9% over the past year.

Price Volatility

Is ALDVI's price volatile compared to industry and market?
ALDVI volatility
ALDVI Average Weekly Movement10.5%
Pharmaceuticals Industry Average Movement5.5%
Market Average Movement6.1%
10% most volatile stocks in FR Market10.5%
10% least volatile stocks in FR Market3.6%

Stable Share Price: ALDVI is more volatile than 90% of French stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: ALDVI's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

FoundedEmployeesCEOWebsite
200732Didier Laurenshttps://www.advicenne.com

Advicenne S.A., a specialty pharmaceutical company, develops and commercializes treatments for nephrology. Its lead product candidate is Sibnayal for the treatment of distal renal tubular acidosis, as well as for the treatment of cystinuria. Advicenne S.A. was founded in 2007 and is headquartered in Paris, France.

Advicenne Fundamentals Summary

How do Advicenne's earnings and revenue compare to its market cap?
ALDVI fundamental statistics
Market Cap€45.47m
Earnings (TTM)-€12.43m
Revenue (TTM)€3.75m

12.1x

P/S Ratio

-3.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALDVI income statement (TTM)
Revenue€3.75m
Cost of Revenue€973.00k
Gross Profit€2.77m
Other Expenses€15.20m
Earnings-€12.43m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Sep 20, 2022

Earnings per share (EPS)-1.26
Gross Margin74.03%
Net Profit Margin-331.65%
Debt/Equity Ratio4,057.0%

How did ALDVI perform over the long term?

See historical performance and comparison

Valuation

Is Advicenne undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


147.2x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ALDVI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ALDVI's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: ALDVI is unprofitable, so we can't compare its PE Ratio to the French Pharmaceuticals industry average.

PE vs Market: ALDVI is unprofitable, so we can't compare its PE Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALDVI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ALDVI is overvalued based on its PB Ratio (147.2x) compared to the FR Pharmaceuticals industry average (2.3x).


Future Growth

How is Advicenne forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


134.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALDVI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.3%).

Earnings vs Market: ALDVI is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ALDVI's is expected to become profitable in the next 3 years.

Revenue vs Market: ALDVI's revenue (47.5% per year) is forecast to grow faster than the French market (5.8% per year).

High Growth Revenue: ALDVI's revenue (47.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ALDVI's Return on Equity is forecast to be low in 3 years time (19.5%).


Past Performance

How has Advicenne performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-27.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ALDVI is currently unprofitable.

Growing Profit Margin: ALDVI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ALDVI is unprofitable, and losses have increased over the past 5 years at a rate of 27.5% per year.

Accelerating Growth: Unable to compare ALDVI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALDVI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9%).


Return on Equity

High ROE: ALDVI has a negative Return on Equity (-4021.68%), as it is currently unprofitable.


Financial Health

How is Advicenne's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ALDVI's short term assets (€16.6M) exceed its short term liabilities (€6.1M).

Long Term Liabilities: ALDVI's short term assets (€16.6M) exceed its long term liabilities (€12.5M).


Debt to Equity History and Analysis

Debt Level: ALDVI has more cash than its total debt.

Reducing Debt: ALDVI had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALDVI has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ALDVI has less than a year of cash runway if free cash flow continues to reduce at historical rates of 26.8% each year


Dividend

What is Advicenne current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALDVI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALDVI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALDVI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALDVI's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ALDVI has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure


CEO

Didier Laurens

1

Tenure

Mr. Didier Laurens serves as Chief Executive Officer at Advicenne S.A. since May 3, 2021 and serves as its Director. He is currently serving as Chief Financial Officer of surgical robotics company eCential...


Leadership Team

Experienced Management: ALDVI's management team is considered experienced (2.5 years average tenure).


Board Members

Experienced Board: ALDVI's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.4%.


Top Shareholders

Company Information

Advicenne S.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: Advicenne S.A.
  • Ticker: ALDVI
  • Exchange: ENXTPA
  • Founded: 2007
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: €45.472m
  • Shares outstanding: 9.89m
  • Website: https://www.advicenne.com

Number of Employees


Location

  • Advicenne S.A.
  • 3ème étage 262
  • Rue du Faubourg Saint-Honore
  • Paris
  • Ile-de-France
  • 75008
  • France

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/20 00:00
End of Day Share Price2022/05/20 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.